glyburide has been researched along with Symptom Cluster in 8 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prado-Carro, AM | 1 |
| Calzada-Hernández, J | 1 |
| Marín, S | 1 |
| Cardona-Hernandez, R | 1 |
| Oriola, J | 1 |
| Nicolás, M | 1 |
| Ramon-Krauel, M | 1 |
| Bouazza, N | 1 |
| Djerada, Z | 1 |
| Gozalo, C | 1 |
| Busiah, K | 1 |
| Beltrand, J | 1 |
| Berdugo, M | 1 |
| Urien, S | 1 |
| Treluyer, JM | 1 |
| Polak, M | 1 |
| Della Manna, T | 1 |
| Battistim, C | 1 |
| Radonsky, V | 1 |
| Savoldelli, RD | 1 |
| Damiani, D | 1 |
| Kok, F | 1 |
| Pearson, ER | 1 |
| Ellard, S | 2 |
| Hattersley, AT | 3 |
| Reis, AF | 1 |
| Mohamadi, A | 1 |
| Clark, LM | 1 |
| Lipkin, PH | 1 |
| Mahone, EM | 1 |
| Wodka, EL | 1 |
| Plotnick, LP | 1 |
| Jones, AG | 1 |
| Sang, Y | 1 |
| Ni, G | 1 |
| Gu, Y | 1 |
| Liu, M | 1 |
| Shimomura, K | 1 |
| Hörster, F | 1 |
| de Wet, H | 1 |
| Flanagan, SE | 1 |
| Wolf, NI | 1 |
| Ashcroft, F | 1 |
| Ebinger, F | 1 |
| Kumar, S | 1 |
| Boulton, AJ | 1 |
1 trial available for glyburide and Symptom Cluster
| Article | Year |
|---|---|
Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.
Topics: Administration, Oral; Blood Glucose; Child; Child, Preschool; Cytochrome P-450 CYP2C9; Dose-Response | 2016 |
7 other studies available for glyburide and Symptom Cluster
| Article | Year |
|---|---|
Patient with iDEND syndrome-related mutation.
Topics: Diabetes Mellitus; Epilepsy; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Infant | 2014 |
Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Topics: Brazil; Child, Preschool; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Female; Glyburide | 2008 |
Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
Topics: Administration, Oral; Adolescent; Continuity of Patient Care; Developmental Disabilities; Diabetes M | 2010 |
Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age.
Topics: Administration, Oral; Adolescent; Amino Acid Substitution; Developmental Disabilities; Diabetes Mell | 2010 |
AV59M KCNJ11 gene mutation leading to intermediate DEND syndrome in a Chinese child.
Topics: Asian People; Developmental Disabilities; Diabetes Mellitus, Type 1; Glyburide; Humans; Hypoglycemic | 2011 |
A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Topics: Animals; Anticonvulsants; Cell Membrane; Child, Preschool; Developmental Disabilities; Diabetes Mell | 2007 |
Serious, prolonged hypoglycaemia with glibenclamide in a patient with Mendenhall's syndrome.
Topics: Abnormalities, Multiple; Adult; Diabetes Mellitus; Glyburide; Humans; Hyperplasia; Hypoglycemia; Hyp | 1993 |